Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2011-4-27
pubmed:databankReference
pubmed:abstractText
The impact of reduced-intensity conditioning (RIC) on the outcomes of hematopoietic cell transplantation (HCT) from unrelated -donors (UD) remains to be determined. We therefore assessed 128 patients, aged 16 to 66 years, with acute leukemia (n = 105) or myelodysplastic syndrome (n = 23) in a UD-HCT trial using RIC with busulfan, fludarabine, and antithymocyte globulin. Patients were transplanted with unmanipulated bone marrow (BM, n = 41) or mobilized peripheral blood mononuclear cells (M-PB, n = 87) and received cyclosporine and methotrexate for graft-versus-host disease (GVHD) prophylaxis. After a median follow-up of 26.7 months (range, 5.9-70.7 months) in surviving patients, 19 patients had died without progression/recurrence of underlying disease, giving a cumulative incidence of transplantation-related mortality (TRM) of 17% (95% confidence interval, 11%-27%; 1-year TRM, 14%). Graft failure (n = 7) and infections (n = 5) were the most common causes of TRM. Only three patients died due to GVHD (acute, one; chronic, two). Graft failure, which occurred in eight patients, showed a significant correlation with graft source (BM, 6/41 vs. M-PB, 2/87; P = 0.009). Donor-patient HLA-disparity did not correlate with GVHD, 1-year TRM, and graft failure. RIC containing antithymocyte globulin led to decreased GVHD-associated, as well as overall, TRM after UD-HCT.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1096-8652
pubmed:author
pubmed:copyrightInfo
Copyright © 2011 Wiley-Liss, Inc.
pubmed:issnType
Electronic
pubmed:volume
86
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
399-405
pubmed:meshHeading
pubmed-meshheading:21523798-Adolescent, pubmed-meshheading:21523798-Adult, pubmed-meshheading:21523798-Antilymphocyte Serum, pubmed-meshheading:21523798-Antineoplastic Agents, pubmed-meshheading:21523798-Bone Marrow Transplantation, pubmed-meshheading:21523798-Busulfan, pubmed-meshheading:21523798-Graft Survival, pubmed-meshheading:21523798-Graft vs Host Disease, pubmed-meshheading:21523798-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:21523798-Humans, pubmed-meshheading:21523798-Immunosuppressive Agents, pubmed-meshheading:21523798-Leukemia, Myeloid, Acute, pubmed-meshheading:21523798-Medical Records, pubmed-meshheading:21523798-Middle Aged, pubmed-meshheading:21523798-Myelodysplastic Syndromes, pubmed-meshheading:21523798-Peripheral Blood Stem Cell Transplantation, pubmed-meshheading:21523798-Precursor Cell Lymphoblastic Leukemia-Lymphoma, pubmed-meshheading:21523798-Retrospective Studies, pubmed-meshheading:21523798-Survival Analysis, pubmed-meshheading:21523798-Transplantation Conditioning, pubmed-meshheading:21523798-Vidarabine, pubmed-meshheading:21523798-Young Adult
pubmed:year
2011
pubmed:articleTitle
Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
pubmed:affiliation
Department of Internal Medicine, Hematology Section, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea. khlee2@amc.seoul.kr
pubmed:publicationType
Journal Article, Clinical Trial, Multicenter Study